KYORIN Pharmaceutical Co., Ltd. (TYO:4569)
Japan · Delayed Price · Currency is JPY 1,266.00
-5.00 (-0.39%)
May 29, 2026, 3:30 PM JST
KYORIN Pharmaceutical Cash Flow Statement
Financials in millions JPY. Fiscal year is April - March.
Millions JPY. Fiscal year is Apr - Mar.
Fiscal Year | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Net Income | 4,451 | 12,770 | 7,019 | 6,906 | 5,216 |
Depreciation & Amortization | 4,663 | 4,603 | 4,290 | 3,840 | 3,714 |
Loss (Gain) From Sale of Assets | 48 | 127 | 90 | 272 | 32 |
Loss (Gain) From Sale of Investments | -368 | 305 | -993 | -674 | 320 |
Loss (Gain) on Equity Investments | -35 | -38 | 12 | - | -25 |
Other Operating Activities | -2,855 | -1,640 | -3,581 | 1,397 | -1,238 |
Change in Accounts Receivable | 241 | 158 | -439 | -5,621 | -1,226 |
Change in Inventory | -2,059 | -12,330 | -5,444 | -5,809 | -3,633 |
Change in Accounts Payable | -1,076 | 1,252 | 319 | 3,085 | 3,875 |
Change in Other Net Operating Assets | 3,371 | -1,701 | 276 | -1,388 | -689 |
Operating Cash Flow | 6,381 | 3,506 | 1,549 | 2,008 | 6,346 |
Operating Cash Flow Growth | 82.00% | 126.34% | -22.86% | -68.36% | 22.30% |
Capital Expenditures | -3,864 | -5,697 | -5,778 | -6,330 | -2,444 |
Sale of Property, Plant & Equipment | 133 | 42 | - | 100 | - |
Divestitures | 41 | - | 921 | - | - |
Sale (Purchase) of Intangibles | -112 | -596 | -468 | -3,075 | -246 |
Investment in Securities | 2,262 | -52 | 2,645 | 3,281 | 317 |
Other Investing Activities | -104 | -20 | -507 | -251 | -187 |
Investing Cash Flow | -1,644 | -6,323 | -3,187 | -6,275 | -2,560 |
Long-Term Debt Issued | 500 | 20,000 | - | - | - |
Total Debt Issued | 500 | 20,000 | - | - | - |
Short-Term Debt Repaid | -4,800 | -2,700 | - | - | - |
Long-Term Debt Repaid | -217 | -10,200 | -200 | -200 | -200 |
Total Debt Repaid | -5,017 | -12,900 | -200 | -200 | -200 |
Net Debt Issued (Repaid) | -4,517 | 7,100 | -200 | -200 | -200 |
Common Dividends Paid | -3,303 | -3,015 | -3,013 | -3,015 | -3,767 |
Other Financing Activities | -136 | -133 | -134 | -148 | -145 |
Financing Cash Flow | -7,956 | 3,952 | -3,347 | -3,363 | -4,112 |
Foreign Exchange Rate Adjustments | - | - | 87 | 241 | 139 |
Miscellaneous Cash Flow Adjustments | - | - | -31 | -83 | 1 |
Net Cash Flow | -3,219 | 1,135 | -4,929 | -7,472 | -186 |
Free Cash Flow | 2,517 | -2,191 | -4,229 | -4,322 | 3,902 |
Free Cash Flow Growth | - | - | - | - | 247.77% |
Free Cash Flow Margin | 1.99% | -1.68% | -3.54% | -3.82% | 3.70% |
Free Cash Flow Per Share | 43.81 | -38.14 | -73.69 | -75.42 | 68.09 |
Cash Interest Paid | 254 | 173 | 66 | 66 | 66 |
Cash Income Tax Paid | 2,865 | 1,317 | 2,975 | 2,065 | 1,248 |
Levered Free Cash Flow | 1,270 | -5,979 | -3,378 | -10,346 | 3,176 |
Unlevered Free Cash Flow | 1,429 | -5,871 | -3,336 | -10,304 | 3,218 |
Change in Working Capital | 477 | -12,621 | -5,288 | -9,733 | -1,673 |